366 related articles for article (PubMed ID: 16038785)
1. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
[TBL] [Abstract][Full Text] [Related]
2. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
Lamba R; Carrum G; Myers GD; Bollard CM; Krance RA; Heslop HE; Brenner MK; Popat U
Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
[TBL] [Abstract][Full Text] [Related]
4. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Yang DH; Lee JJ; Kim YK; Kim HJ; Shin HJ; Chung JS; Cho GJ
Am J Hematol; 2008 Aug; 83(8):649-53. PubMed ID: 18528826
[TBL] [Abstract][Full Text] [Related]
5. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
[TBL] [Abstract][Full Text] [Related]
6. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab for the prevention and treatment of graft-versus-host disease.
Kanda J; Lopez RD; Rizzieri DA
Int J Hematol; 2011 May; 93(5):586-593. PubMed ID: 21369856
[TBL] [Abstract][Full Text] [Related]
8. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation.
Bertz H; Spyridonidis A; Wäsch R; Grüllich C; Egger M; Finke J
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1563-70. PubMed ID: 19896080
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation.
Jiménez M; Martínez C; Ercilla G; Carreras E; Urbano-Ispízua A; Aymerich M; Villamor N; Amézaga N; Rovira M; Fernández-Avilés F; Gaya A; Martino R; Sierra J; Montserrat E
Exp Hematol; 2005 Oct; 33(10):1240-8. PubMed ID: 16219547
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.
Barge RM; Starrenburg CW; Falkenburg JH; Fibbe WE; Marijt EW; Willemze R
Bone Marrow Transplant; 2006 Jun; 37(12):1129-34. PubMed ID: 16757974
[TBL] [Abstract][Full Text] [Related]
11. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
Gärtner F; Hieke S; Finke J; Bertz H
Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
[TBL] [Abstract][Full Text] [Related]
12. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
[TBL] [Abstract][Full Text] [Related]
13. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
[TBL] [Abstract][Full Text] [Related]
16. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
17. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
[TBL] [Abstract][Full Text] [Related]
18. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
19. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
Kanda Y; Oshima K; Kako S; Fukuda T; Uchida N; Miyamura K; Kondo Y; Nakao S; Nagafuji K; Miyamoto T; Kurokawa M; Okoshi Y; Chiba S; Ohashi Y; Takaue Y; Taniguchi S
Am J Hematol; 2013 Apr; 88(4):294-300. PubMed ID: 23450467
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
Das-Gupta EP; Russell NH; Shaw BE; Pearce RM; Byrne JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):724-33. PubMed ID: 17531783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]